Ranibizumab biosimilar is under clinical development by Incepta Pharmaceuticals and currently in Phase III for Diabetic Macular Edema. According to GlobalData, Phase III drugs for Diabetic Macular Edema have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ranibizumab biosimilar overview
Ranibizumab biosimilar is under development for the treatment of diabetic macular edema (DME). It is administered through intravitreal route and acts by targeting vascular endothelial growth factor A (VEGFA).
Incepta Pharmaceuticals overview
Incepta Pharmaceuticals (Incepta) manufactures and markets pharmaceutical products. The company offers its products in various therapeutic categories including anti emetic, anti bacterial, anti inflammatory, anti diabetic, anti gout, anti histamine, anti obesity, anti spasmodic, anti protozoal, anti viral medicines and others. Incepta produces various types of dosage forms including tablets, dry powder vials, powder for suspension, capsules, oral liquids, ampoules, nasal sprays, eye drops, creams, liquid filled hard gelatin capsules, ointments, lotions, gels, prefilled syringes, lyophilized injections, human vaccine and others. The company operates manufacturing facility in Savar. It distributes its products through a network of distributors across the country. Incepta is headquartered in Dhaka, Bangladesh.
For a complete picture of Ranibizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
